AstraZeneca has reported a record quarter for revenue including $1.8bn from its Covid-19 vaccine and sales from its $39bn acquisition of rare disease company Alexion.
Total revenue at the UK drugmaker soared 63 per cent year-on-year to $12bn in the fourth quarter, on a constant currency basis, higher than the consensus forecast for $11bn. Two cancer drugs — Tagrisso and Lynparza — and Soliris for a rare disease each generated more than $1bn in the three-month period.
Core earnings per share rose 74 per cent to $1.67, above the average analyst estimate for 73 cents.
您已阅读36%（570字），剩余64%（995字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。